We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Whoops. AMC have bought 1 million dollar's worth of ArtemiC but I interpreted the news that Graft Polymer was producing the 50,000 units worth the above amount not actually receiving that amount to finish the job. They will all profit.
MGC has a licensing agreement with Graft Polymer who received the 1 million dollar order to to produce 50,000 Artemic Rescue nutraceuticals to fulfil a bulk order from US based AMC Holdings who are presumably distributing this order for MGC in the US. Graft Polymer say this production order here will be fulfilled over the next 3 months.
Graft Polymer UK. Is a "UK - based food supplement and drug delivery system developer who develop intellectual property for pharma applications. Just looks like these agencies are working together to profit from MGC's products.
No flat earther here. Merely concerned r.e the structure of the deal between AMC, mgc, and graft polymer and potential benefits to Roby and absence of benefits to us. I am obviously in no way disputing the conditions attached to the options. You did not address the concerns I raised r.e the structuring, merely pointed out he has only satisfied one of the conditions thus far....
Page 20 of the last financial accounts. The 1m is only part of the conditions and the options are also contingent on share price movement. More world is flat believers here than anywhere else!
Remuneration policy
The remuneration policy of the Company was that each director entered into a service agreement with the Group on a salary per annum, with Roby Zomer, Victor Bolduev and Pavel Kobzev also earning a salary under Graft Polymer d.o.o. Since re-admission subsequent to period-end, a remuneration committee has been appointed to reassess an appropriate level of Directors’ remuneration and it is envisaged that the remuneration policy will assist to attract, retain and motive Executive Directors and senior management of a high calibre with a view to encouraging commitment to the development of the Company and for long term enhancement of shareholder value. The Board believes that share ownership by Directors strengthens the link between their personal interests and those of shareholders.
The current Directors’ remuneration comprises a basic fee and at period end, there was no bonus of long-term incentive plan in operation for Directors.
Subsequent to period end and upon admission to the LSE, the directors were granted options over Ordinary Shares pursuant to a Share Option Scheme, of which are detailed below:
Director
Roby Zomer Victor Bolduev Pavel Kobzev Alex Brooks Yifat Steuer
Number of Ordinary Share under option
1,700,000 2,200,000 1,600,000 1,000,000 1,673,611
Weighted Average Exercise Price per Ordinary Share £
£0.001 £0.001 £0.001 £0.001 £0.001
One third of the options will vest on satisfaction of the first milestone and two thirds will vest on the satisfaction of the second milestone. The milestones are as follows:
l first milestone:
o the Company’s share price reaching appreciation of 125 per cent. of the Issue Price based on a 15-day
volume weighted average price in the period 12 months from the date of Admission; and
o the generation by the Group of revenue in a twelve-month period of EURO1,000,000 or more.
l second milestone:
o the Company’s share price reaching appreciation of 150 per cent. based on a 15-day volume weighted
average price in the period 24 months from Admission; and
o the generation by the Group of revenue in a twelve-month period of EURO5,000,000 or more.
Wouldn’t this be classed as a conflict or Interest if this were true. Can you again share the source of this info?
Not much of a tweeter tbh, leave it those better qualified!
Put it on Twitter so Roby can see it
Both facilities listed at: Emonska cesta 8-1000, 1000 Ljubljana, Slovenia. So we're paying another company to manufacture our product in our factory and making no money from the deal?? This seems ridiculous, starting to wish I had listened to the Aussies on here shortly after listing
It's fair to say no one trusts this company.
*their
More so that the purchase agreement by mgc from graf was designed to do exactly that. We seem to have received a £1M for Artemic yet we pay the company that owns the delivery system the same total amount? Therefore artemic is worth £0 and grafts delivery system £1M? The result ; Roby in line for a payday and mgc realises no net benefit.
Also curious if our and there Slovenia site is one and the same, will check later...
Are you deducing from this statement Roby is triggering a share option clause based on the recent RNS of the $1M order?
From garftpolymer annual accounts? It's most recent filing for them on companies House dated aug 11: https://find-and-update.company-information.service.gov.uk/company/10776788/filing-history
Have you got the extract that says that GMF
Just seen on graftpolymers annual accounts on companies House that one of the milestones required for Roby to get a large share options is generating €1M in revenue, funny timing that...
I seem to recall a few posters a year or so ago calling Roby's probity into question, anyone got more info r.e this?
You ask why we would want to be taken over by a big pharma, well if they offered £1 tomorrow or you could wait a few years to see how the company develops I think most would accept the takeover offer.
Ah I see: "Graft Polymer have licenced its drug delivery system platform to MGC Pharma to deliver active ingredients more effectively to improve the bioavailability and synergy of the natural ingredients". From graft polymer RNS.
Also used for Cannepil and on glioblastoma trials recently, so if in the future there is orders fro either of the above, will there be similar minimal benefit to be had and the money funneled back to Roby at Graft polymer?
Appears also from graft polymer RNS that they transferred the obtained patents to a subsidiary; Graft Polymer UK IP. In which Roby is also a director, just me that thinks this seems, well odd? Would like to be missing something glaringly obvious however
Yet with news of purchase from another of Roby's entities for same amount, I'm struggling to see the commercial gain here? Who owns the patent to artemic? Apologies if I've missed this, couldn't see on any RNS.
MGC Pharma is excited to be at the forefront of phytomedicinal research, and the opportunity to enter the world’s largest, and most advanced Healthcare market, and we look forward to the insight that AMC will bring to the future clinical development of ArtemiC.
Would love to be as optimistic - but wouldn't be at all surprised to see a fall in price on the back of another positive RNS.....
Good RNS, here’s to a bounce in the share price.
Another excellent piece of commercial news today from the company. Big pharma will be watching what’s going on here and at some stage a takeover will surely be on the cards. Good luck, Brighty
Hopefully 15-20% plus day today but seems MM want to hold it back for some reason.
Out